{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:48:55Z","timestamp":1768294135166,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004628","name":"AstraZeneca UK Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.vaccine.2019.06.016","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T21:46:38Z","timestamp":1562190398000},"page":"4543-4550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Haemagglutinin stability was not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against A\/H1N1pdm09 viruses in the 2013\u20132014 and 2015\u20132016 seasons"],"prefix":"10.1016","volume":"37","author":[{"given":"Lauren","family":"Parker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Maeso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Bright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Dibben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.06.016_b0005","unstructured":"World Health Organisation. Influenza: fact sheet No211. 2003. Available from: [Accessed August 2, 2018]. <http:\/\/www.who.int\/mediacentre\/factsheets\/2003\/fs211\/en\/>."},{"key":"10.1016\/j.vaccine.2019.06.016_b0010","unstructured":"Public Health England. The Winter 2018\/19 Flu Vaccination. 2018. Available from: [Accessed October 25, 2018]. <https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/745949\/PHE_flu_vaccination_A5_booklet.pdf>."},{"key":"10.1016\/j.vaccine.2019.06.016_b0015","unstructured":"Centers for Disease Control and Prevention. Prevention strategies for seasonal influenza in healthcare settings. 2018. Available from: [Accessed October 25, 2018]. <https:\/\/www.cdc.gov\/flu\/professionals\/infectioncontrol\/healthcaresettings.htm>."},{"key":"10.1016\/j.vaccine.2019.06.016_b0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1750-2659.2008.00056.x","article-title":"Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza","volume":"2","author":"Ambrose","year":"2008","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2019.06.016_b0025","unstructured":"European Medicines Agency. Fluenz influenza vaccine (live attenuated, nasal). 2014. Available from: [Accessed August 2, 2018]. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/001101\/WC500103712.pdf>."},{"key":"10.1016\/j.vaccine.2019.06.016_b0030","unstructured":"Department of Health and Human Services. Clinical review of supplemental biologics license application for MedImmune\u2019s quadrivalent live attenuated influenza vaccine (Q\/LAIV). 2012. Available from: [Accessed August 2, 2018]. <https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm295380.pdf>."},{"key":"10.1016\/j.vaccine.2019.06.016_b0035","unstructured":"European Medicines Agency. Assessment report: fluenz tetra: common name: influenza vaccine (live attenuated, nasal). 2013. Available from: [Accessed August 2, 2018]. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002617\/WC500158413.pdf>."},{"key":"10.1016\/j.vaccine.2019.06.016_b0040","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1016\/j.vaccine.2016.08.079","article-title":"Association of vaccine handling conditions with effectiveness of live attenuated influenza vaccine against H1N1pdm09 viruses in the United States","volume":"34","author":"Caspard","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.016_b0045","doi-asserted-by":"crossref","first-page":"e1003831","DOI":"10.1371\/journal.ppat.1003831","article-title":"A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity","volume":"10","author":"Cotter","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2019.06.016_b0050","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1128\/JVI.02278-13","article-title":"Structural stability of influenza A(H1N1)pdm09 virus hemagglutinins","volume":"88","author":"Yang","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.06.016_b0055","doi-asserted-by":"crossref","first-page":"RRN1162","DOI":"10.1371\/currents.RRN1162","article-title":"A new common mutation in the hemagglutinin of the 2009 (H1N1) influenza A virus","volume":"2","author":"Maurer-Stroh","year":"2010","journal-title":"PLoS Curr"},{"key":"10.1016\/j.vaccine.2019.06.016_b0060","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.vaccine.2010.12.044","article-title":"The development of vaccine viruses against pandemic A(H1N1) influenza","volume":"29","author":"Robertson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.016_b0065","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.vaccine.2010.12.120","article-title":"Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain","volume":"29","author":"Farnsworth","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.016_b0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1472-6750-12-77","article-title":"Pandemic influenza vaccine: characterization of A\/California\/07\/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability","volume":"12","author":"Feshchenko","year":"2012","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.vaccine.2019.06.016_b0075","doi-asserted-by":"crossref","first-page":"ofx111","DOI":"10.1093\/ofid\/ofx111","article-title":"Live-attenuated influenza vaccine effectiveness in children from 2009 to 2015\u20132016: a systematic review and meta-analysis","volume":"4","author":"Caspard","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.016_b0080","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.45.30394","article-title":"Letter to the editor: potential causes of the decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines","volume":"21","author":"Ambrose","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2019.06.016_b0085","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.38.30350","article-title":"Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge?","volume":"21","author":"Penttinen","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2019.06.016_b0090","first-page":"9","article-title":"Live attenuated influenza vaccine contains substantial and unexpected amounts of defective viral genomic","author":"Gould","year":"2017","journal-title":"RNA Viruses"},{"key":"10.1016\/j.vaccine.2019.06.016_b0095","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/S1473-3099(17)30360-2","article-title":"Urgent challenges in implementing live attenuated influenza vaccine","volume":"18","author":"Singanayagam","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.016_b0100","doi-asserted-by":"crossref","first-page":"e183742","DOI":"10.1001\/jamanetworkopen.2018.3742","article-title":"Association of prior vaccination with influenza vaccine effectiveness in children receiving live attenuated or inactivated vaccine","volume":"1","author":"McLean","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2019.06.016_b0105","first-page":"93","article-title":"Acid-induced membrane fusion by the hemagglutinin protein and its role in influenza virus biology","volume":"385","author":"Russell","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"issue":"Pt 12","key":"10.1016\/j.vaccine.2019.06.016_b0110","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1099\/0022-1317-67-12-2813","article-title":"Time and temperature dependence of influenza virus membrane fusion at neutral pH","volume":"67","author":"Haywood","year":"1986","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.06.016_b0115","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0042-6822(86)90210-2","article-title":"Conformational changes in the hemagglutinin of influenza virus which accompany heat-induced fusion of virus with liposomes","volume":"155","author":"Ruigrok","year":"1986","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.06.016_b0120","doi-asserted-by":"crossref","first-page":"21590","DOI":"10.1074\/jbc.M117.815043","article-title":"Probing the metastable state of influenza hemagglutinin","volume":"292","author":"Kingsley","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2019.06.016_b0125","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/INF.0b013e31806166f8","article-title":"Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia","volume":"26","author":"Tam","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.06.016_b0130","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1542\/peds.2006-0725","article-title":"Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care","volume":"118","author":"Vesikari","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2019.06.016_b0135","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/01.inf.0000237829.66310.85","article-title":"Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections","volume":"25","author":"Ashkenazi","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.06.016_b0140","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/01.inf.0000237797.14283.cf","article-title":"Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma","volume":"25","author":"Fleming","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.06.016_b0145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMoa065368","article-title":"Live attenuated versus inactivated influenza vaccine in infants and young children","volume":"356","author":"Belshe","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.06.016_b0150","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.vaccine.2017.03.085","article-title":"Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014\u20132015 season","volume":"35","author":"McLean","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.016_b0155","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/cid\/ciw635","article-title":"2014\u20132015 influenza vaccine effectiveness in the united states by vaccine type","volume":"63","author":"Zimmerman","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.016_b0160","article-title":"Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014\/15 end of season results","volume":"20","author":"Pebody","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2019.06.016_b0165","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1073\/pnas.100133697","article-title":"A DNA transfection system for generation of influenza A virus from eight plasmids","volume":"97","author":"Hoffmann","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2019.06.016_b0170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1128\/JVI.02106-09","article-title":"Generation of live attenuated novel influenza virus A\/California\/7\/09 (H1N1) vaccines with high yield in embryonated chicken eggs","volume":"84","author":"Chen","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.06.016_b0175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0042-6822(02)00035-1","article-title":"Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A\/Ann Arbor\/6\/60","volume":"306","author":"Jin","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.06.016_b0180","doi-asserted-by":"crossref","first-page":"11014","DOI":"10.1128\/JVI.79.17.11014-11021.2005","article-title":"Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B\/Ann Arbor\/1\/66","volume":"79","author":"Hoffmann","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.06.016_b0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2012.06.002","article-title":"Surface glycoproteins of influenza A H3N2 virus modulate virus replication in the respiratory tract of ferrets","volume":"432","author":"Cheng","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.06.016_b0190","series-title":"Robust statistics","author":"Huber","year":"2009"},{"key":"10.1016\/j.vaccine.2019.06.016_b0195","doi-asserted-by":"crossref","first-page":"e1003151","DOI":"10.1371\/journal.ppat.1003151","article-title":"Influenza HA subtypes demonstrate divergent phenotypes for cleavage activation and pH of fusion: implications for host range and adaptation","volume":"9","author":"Galloway","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2019.06.016_b0200","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1128\/JVI.01927-14","article-title":"Variations in pH sensitivity, acid stability, and fusogenicity of three influenza virus H3 subtypes","volume":"89","author":"Costello","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.06.016_b0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0264-410X(85)90109-4","article-title":"Stability of infectious influenza A viruses at low pH and at elevated temperature","volume":"3","author":"Scholtissek","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.06.016_b0210","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1073\/pnas.1524384113","article-title":"Molecular requirements for a pandemic influenza virus: An acid-stable hemagglutinin protein","volume":"113","author":"Russier","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2019.06.016_b0215","doi-asserted-by":"crossref","first-page":"e01621","DOI":"10.1128\/JVI.01621-17","article-title":"A Y161F hemagglutinin substitution increases thermostability and improves yields of 2009 H1N1 influenza a virus in cells","volume":"92","author":"Wen","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.06.016_b0220","doi-asserted-by":"crossref","first-page":"12374","DOI":"10.1128\/JVI.01107-14","article-title":"The matrix gene segment destabilizes the acid and thermal stability of the hemagglutinin of pandemic live attenuated influenza virus vaccines","volume":"88","author":"O'Donnell","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.06.016_b0225","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.cmi.2016.07.007","article-title":"Functional balance between neuraminidase and haemagglutinin in influenza viruses","volume":"22","author":"Gaymard","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2019.06.016_b0230","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1099\/vir.0.059477-0","article-title":"Entry of influenza A virus: host factors and antiviral targets","volume":"95","author":"Edinger","year":"2014","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2019.06.016_b0235","first-page":"8","article-title":"The Feat of Packaging Eight Unique Genome Segments","author":"Giese","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2019.06.016_b0240","doi-asserted-by":"crossref","first-page":"643","DOI":"10.15585\/mmwr.mm6722a5","article-title":"Update: ACIP recommendations for the use of quadrivalent live attenuated influenza vaccine (LAIV4) \u2014 United States, 2018\u201319 Influenza Season","volume":"67","author":"Grohskopf","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T21:56:32Z","timestamp":1663883792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19307777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":48,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0264410X19307777"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Haemagglutinin stability was not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against A\/H1N1pdm09 viruses in the 2013\u20132014 and 2015\u20132016 seasons","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}